<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02939391</url>
  </required_header>
  <id_info>
    <org_study_id>6356-002</org_study_id>
    <nct_id>NCT02939391</nct_id>
  </id_info>
  <brief_title>A Study of KW-6356 in Subjects With Early Parkinson's Disease</brief_title>
  <official_title>An Early Phase 2 Study of KW-6356 in Subject With Early Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Hakko Kirin Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Hakko Kirin Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate the effect of KW-6356 on motor symptoms in Parkinson's
      disease and the primary endpoint is the change from baseline in the MDS-UPDRS part III score
      between KW-6356 and placebo in subjects with early Parkinson's disease in Japan.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Actual">December 8, 2017</completion_date>
  <primary_completion_date type="Actual">November 22, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the Movement disorder society-unified Parkinson's disease rating scale(MDS-UPDRS) partⅢ score</measure>
    <time_frame>Up to 12 weeks after dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical global impression-improvement(CGI-I) score</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient global impression-improvement(PGI-I) score</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Parkinson's disease questionnaire-39(PDQ-39) total scores</measure>
    <time_frame>Up to 12 weeks after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects with treatment-emergent adverse events</measure>
    <time_frame>Up to 14 weeks after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profiles of pharmacokinetics of plasma KHK6356 concentration</measure>
    <time_frame>2, 4, 8 and 12 weeks after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the MDS-UPDRS subitem and total scores</measure>
    <time_frame>Up to 12 weeks after dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">175</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>KW-6356 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KW-6356 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KW-6356</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>KW-6356 Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KW-6356</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>KW-6356 High Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject fulfills the UK Parkinson's Disease Society brain bank clinical diagnostic
             criteria

          -  Parkinson's disease patients in Stages 1 to 3 on the Modified Hoehn and Yahr Scale

          -  MDS-UPDRS part III score of ≥ 15

        Exclusion Criteria:

          -  Use of any CYP3A4/5-related drugs within 2 weeks prior to enrollment.

          -  Use of any of the specified antiparkinsonian drugs and dopamine antagonists during the
             specified period.

          -  Treatment with levodopa/DCI at any time in the past for a period of 4 weeks or more.

          -  Neurosurgical operation for Parkinson's disease (stereotactic surgery, deep brain
             stimulation or gamma knife), or treatment by transcranial magnetic stimulation (TMS).

          -  Either of the following criteria consecutively at screening and enrollment;

               -  Resting Pulse &gt; 100 bpm

               -  Resting systolic blood pressure &gt; 140 mmHg, or diastolic blood pressure &gt; 90 mmHg

          -  Significant dementia or a Mini-Mental State Examination (MMSE) score of ≤ 23.

          -  Subject has a history or evidence of suicidal ideation (severity of 4 or 5) or any
             suicidal behavior based on an assessment with the Columbia-Suicide Severity Rating
             Scale (C-SSRS) at baseline.

          -  Anyone otherwise considered unsuitable for the study by the investigator or
             sub-investigator including those who are unable to communicate or to cooperate with
             the investigator or sub-investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Asahikawa City</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Akashi</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fujisawa</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nakano</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Setagaya</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2016</study_first_submitted>
  <study_first_submitted_qc>October 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2016</study_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

